Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.40% |
| SUPPORTCOM I | SPRT | 3.75% |
| UNISYS CORP | UIS | 3.31% |
| SHORETEL INC | SHOR | 3.22% |
| GREEN MOUNTA | GMCR | 3.13% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Zimmer Holdings Inc. (ZMH - Analyst Report) introduced its first lateral plate system for the spinal trauma segment titled Zimmer V2F Anterior Fixation System. The company’s new implant system can be used as a remedy for thoracolumbar burst fractures, tumors, disc degeneration and other pathologies of the anterior spine.
Zimmer’s V2F system, built on the company’s proprietary technology, includes a wide range of plates and screws to suit the varying anatomy of the thoracolumbar spine. The system offers flexibility for placement of screws at different angles to fit the patient’s anatomical structure. Based on the unique variable-to-fixed screw and cap technology, the V2F system is expected to improve patient outcomes.
The company currently enjoys 3% share in the $9 billion spinal market. This is expected to improve going forward as Zimmer is working on portfolio expansion and works to gain a foothold in the emerging markets.
We note that revenues from spinal products (accounting for approximately 5% of total revenues) have been languishing over the last few quarters. We are encouraged by Zimmer’s attempt to expand its spinal portfolio to provide some cushion to its struggling sales.
Neutral on Zimmer
Given the challenging macroeconomic conditions, the company’s strategy of new product launches, employment of new technologies and expansion into emerging markets is likely to pay off. Its peers in the reconstructive market Smith & Nephew (SNN - Snapshot Report) and Stryker Corporation (SYK - Analyst Report) have adopted the inorganic route to battle macroeconomic headwinds.
The situation is expected to improve as procedural deferrals reduce with time. As the situation gradually improves, Zimmer is well poised in the industry to reap the benefits of a recovering economy. Given the lack of positive driving events, the stock carries a Zacks Rank #3 (Hold).
Though we remain non-committal on this provider of reconstructive implant and trauma products we look forward to other players in the orthopedic space such as Hanger Orthopedic (HGR) which carries Zacks Rank #2 (Buy).
Get the full Analyst Report on SYK - FREE
Get the full Analyst Report on ZMH - FREE
Get the full Snapshot Report on SNN - FREE